Regenicin Inc (RGIN):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Regenicin Inc (RGIN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8185
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:25
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Regenicin Inc (Regenicin), formerly Windstar Inc is a biotechnology company that develops regenerative cell therapies. The company offers NovaDerm, a tissue-engineered skin prepared from autologous skin cells. Its NovaDerm technology uses the patient’s own skin cells to generate living, tissue-engineered skin for the treatment of severe burns. Regenicin offers banked allogenic cell products for treatment of chronic wounds, cosmetic and other topical testing, and medical testing services. The company develops products for diabetes and chronic wounds including ulcers, adult stem cell therapies and reconstructive surgical applications. It has operations throughout the US. Regenicin is headquartered in Little Falls, New Jersey, the US.

Regenicin Inc (RGIN) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Regenicin Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Regenicin Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Regenicin Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Regenicin Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Regenicin Inc, Medical Devices Deals, 2012 to YTD 2018 9
Regenicin Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Regenicin Inc, Pharmaceuticals & Healthcare, Deal Details 11
Debt Offering 11
Regenicin Raises USD0.1 Million in Private Placement of 8% Note Due May 2014 11
Regenicin Raises USD0.3 Million in Private Placement of 8% Notes Due 2014 12
Regenicin Raises Funds through Private Placement of 8% Note Due November 2013 13
Regenicin Raises USD0.1 Million in Private Placement of 10% Note Due June 2013 14
Regenicin Raises USD0.1 Million in Private Placement of 10% Note Due January 2013 15
Regenicin Raises Funds through Private Placement of 33% Note Due October 2012 16
Regenicin Raises USD0.2 Million in Private Placement of 33% Note Due November 2012 17
Regenicin Raises USD0.2 Million in Private Placement of 33% Note Due 2012 18
Regenicin Raises USD0.1 Million in Private Placement of 8% Note Due March 2012 19
Regenicin Raises USD0.16 Million in Private Placement of 5% Note Due June 2012 20
Regenicin Inc – Key Competitors 21
Regenicin Inc – Key Employees 22
Regenicin Inc – Locations And Subsidiaries 23
Head Office 23
Other Locations & Subsidiaries 23
Recent Developments 24
Financial Announcements 24
Jan 18, 2017: Regenicin Reports 2016 Operating Results, Outlines Milestones for 2017 24
Appendix 25
Methodology 25
About GlobalData 25
Contact Us 25
Disclaimer 25

List of Tables
Regenicin Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Regenicin Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Regenicin Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Regenicin Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Regenicin Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Regenicin Inc, Medical Devices Deals, 2012 to YTD 2018 9
Regenicin Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Regenicin Raises USD0.1 Million in Private Placement of 8% Note Due May 2014 11
Regenicin Raises USD0.3 Million in Private Placement of 8% Notes Due 2014 12
Regenicin Raises Funds through Private Placement of 8% Note Due November 2013 13
Regenicin Raises USD0.1 Million in Private Placement of 10% Note Due June 2013 14
Regenicin Raises USD0.1 Million in Private Placement of 10% Note Due January 2013 15
Regenicin Raises Funds through Private Placement of 33% Note Due October 2012 16
Regenicin Raises USD0.2 Million in Private Placement of 33% Note Due November 2012 17
Regenicin Raises USD0.2 Million in Private Placement of 33% Note Due 2012 18
Regenicin Raises USD0.1 Million in Private Placement of 8% Note Due March 2012 19
Regenicin Raises USD0.16 Million in Private Placement of 5% Note Due June 2012 20
Regenicin Inc, Key Competitors 21
Regenicin Inc, Key Employees 22
Regenicin Inc, Subsidiaries 23

List of Figures
Regenicin Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Regenicin Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Regenicin Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Regenicin Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Regenicin Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Regenicin Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Regenicin Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Regenicin Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Regenicin Inc, Medical Devices Deals, 2012 to YTD 2018 9

★海外企業調査レポート[Regenicin Inc (RGIN):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Greenbelt Resources Corp (GRCO):電力:M&Aディール及び事業提携情報
    Summary Greenbelt Resources Corp (GRC) is an alternative energy company that offers sustainable energy production systems delivering modular solutions that enable localized processing of locally generated waste into locally consumed products. The company designs, develops and implements technology t …
  • The Miyazaki Bank Ltd.:企業の戦略・SWOT・財務情報
    The Miyazaki Bank Ltd. - Strategy, SWOT and Corporate Finance Report Summary The Miyazaki Bank Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Thermax Ltd (THERMAX):企業の財務・戦略的SWOT分析
    Thermax Ltd (THERMAX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Li Ning Company Ltd (2331)
    Li Ning Company Ltd (2331) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company
  • CorMedix Inc (CRMD):製薬・医療:M&Aディール及び事業提携情報
    Summary CorMedix Inc (CorMedix) is a commercial-stage pharmaceutical company that develops and commercializes therapeutic products for prevention and treatment of cardiac, renal and infectious diseases. The company offers neutrolin, a non-antibiotic anti-infective developed as a preventative solutio …
  • Ameresco Inc (AMRC):企業の財務・戦略的SWOT分析
    Ameresco Inc (AMRC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Expro Holdings UK 2 Limited:企業の戦略的SWOT分析
    Expro Holdings UK 2 Limited - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major product …
  • Stereotaxis Inc (STXS)-製薬・医療分野:企業M&A・提携分析
    Summary Stereotaxis Inc (Stereotaxis) is a healthcare technology company that designs, manufactures and markets robotic systems and instruments for electrophysiologists for the treatment of cardiac arrhythmias. Its flagship product, Epoch Solution is an advanced remote robotic navigation system for …
  • NCC Ltd (NCC):企業の財務・戦略的SWOT分析
    NCC Ltd (NCC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the pot …
  • Landis+Gyr AG (LAND):企業の財務・戦略的SWOT分析
    Landis+Gyr AG (LAND) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Grant Thornton International Ltd:企業の戦略的SWOT分析
    Grant Thornton International Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pr …
  • Tubacero S. de RL de CV:企業の戦略・SWOT・財務分析
    Tubacero S. de RL de CV - Strategy, SWOT and Corporate Finance Report Summary Tubacero S. de RL de CV - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Hydro-Electric Corporation:企業の戦略的SWOT分析
    Hydro-Electric Corporation - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Lotte Chemical Corp (011170):企業の財務・戦略的SWOT分析
    Lotte Chemical Corp (011170) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Greenpower Energy Ltd (GPP):石油・ガス:M&Aディール及び事業提携情報
    Summary Greenpower Energy Ltd (Greenpower) is an oil and gas, and mineral exploration and development company. The company’s business activities include acquisition, exploration, and development of petroleum, mineral and hydrothermal exploration properties. It explores for coal, lithium, tantalum, p …
  • Spanish National Cancer Research Center:製薬・医療:M&Aディール及び事業提携情報
    Summary Spanish National Cancer Research Center (CNIO) is a medical research center that conducts cancer research programs. The center integrates basic and translational cancer research. It conducts various scientific programs, which include molecular oncology program, structural biology and biocomp …
  • Gujarat State Electricity Corporation Ltd:企業の戦略的SWOT分析
    Gujarat State Electricity Corporation Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and …
  • JAND, Inc.:医療機器:M&Aディール及び事業提携情報
    Summary JAND, Inc. (JIN), doing business a warby parker, is a manufacturing company. The company engages in operations of optical manufacturer. JIN product portfolio consists of eyeglasses, sunglasses, and gift cards. The company also manufactures and sale of eyewear for men and women. It also offer …
  • NewLink Genetics Corp (NLNK):製薬・医療:M&Aディール及び事業提携情報
    Summary NewLink Genetics Corp (NewLink) is a clinical stage immuno-oncology company that discovers and develops novel immunotherapeutic products for the treatment of cancer. Its products include small-molecule and biologic immuno-oncology products. NewLink utilizes its HyperAcute cellular immunother …
  • Hino Motors Ltd (7205):企業の財務・戦略的SWOT分析
    Hino Motors Ltd (7205) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆